Kawazoe, Hitoshi

写真a

Affiliation

Faculty of Pharmacy, Department of Pharmacy 医療薬学・社会連携センター 医療薬学部門 (Shiba-Kyoritsu)

Position

Associate Professor

Career 【 Display / hide

  • 2022.09
    -
    Present

    国立がん研究センター東病院 腫瘍内科 任意研修生

  • 2022.04
    -
    Present

    慶應義塾大学薬学部 准教授

  • 2020.04
    -
    Present

    愛媛大学大学院医学系研究科 臨床腫瘍学講座 客員研究員

  • 2018.04
    -
    2022.03

    慶應義塾大学薬学部 専任講師

  • 2008.04
    -
    2018.03

    愛媛大学医学部附属病院 薬剤部

display all >>

Academic Background 【 Display / hide

  • 2004.04
    -
    2008.03

    The University of Tokushima, 薬科学教育部 医療生命薬学専攻 博士後期課程

    Graduate School, Completed, Doctoral course

  • 2001.04
    -
    2003.03

    The University of Tokushima, 薬学研究科 医療薬学専攻 博士前期課程

    Graduate School, Completed, Master's course

  • 1997.04
    -
    2001.03

    The University of Tokushima, 薬学部, 薬学科

    University, Graduated

Academic Degrees 【 Display / hide

  • 博士(薬学), The University of Tokushima, Coursework, 2008.03

    がん治療関連毒性に対する薬物療法に関する臨床薬学的研究

Licenses and Qualifications 【 Display / hide

  • 日本医療薬学会医療薬学専門薬剤師認定, 2020.01

  • 日本医療薬学会医療薬学指導薬剤師認定, 2020.01

  • 日本医療薬学会がん専門薬剤師認定, 2010.01

  • 日本医療薬学会がん指導薬剤師認定, 2010.01

  • 日本MBTI協会MBTI認定ユーザー, 2018.12

display all >>

 

Research Areas 【 Display / hide

  • Life Science / Clinical pharmacy

Research Keywords 【 Display / hide

  • がん治療関連毒性の臨床薬学的研究

Research Themes 【 Display / hide

  • 卒前・卒後教育による次世代リーダー育成、がん薬物治療に関する薬効・安全性学的研究, 

    2021.04
    -
    Present

 

Books 【 Display / hide

  • 調剤と情報7月増刊号

    菊山史博, 井上賀絵, 河添 仁, じほう, 2023.07,  Page: 294-307, 395-399

    Scope: 【こんなときはどの検定?臨床研究から学ぶ"逆引き"統計】第5章 分散分析と多重比較編 パラメトリック多重比較→Tukey-Kramer、Dunnett検定

  • 検査値と画像データから読み解く 薬効・副作用評価マニュアル

    河添 仁, 医学書院, 2022.08,  Page: 399-407

    Scope: 腫瘍マーカー・がん関連遺伝子検査

  • Principal Pharmacotherapy改訂3版

    河添 仁, ネオメディカル, 2022.03,  Page: 632-636

    Scope: 乳がん

  • 明日から使える免疫関連有害事象マネジメント 免疫チェックポイント阻害薬の看護ケア

    河添 仁, 南江堂, 2022.02,  Page: 105

    Scope: 編集にあたって

  • 薬剤師が実践すべき副作用へのロジカルアプローチ その症状, きちんと評価できていますか?

    河添 仁, 南江堂, 2021.09,  Page: 217-227

    Scope: めまい・耳鳴

display all >>

Papers 【 Display / hide

  • Proton Pump Inhibitors and Cyclin-Dependent Kinase 4/6 Inhibitors in Patients With Breast Cancer

    Takahashi K, Uozumi R, Mukohara T, Hayashida T, Iwabe M, Iihara H, Kusuhara-Mamishin K, Kitagawa Y, Tsuchiya M, Kitahora M, Nagayama A, Kosaka S, Asano-Niwa Y, Seki T, Ohnuki K, Suzuki A, Ono F, Futamura M, Kawazoe H*, Nakamura T

    Oncologist (Oxford University Press)  in press. 2024.03

    Research paper (scientific journal), Joint Work, Corresponding author, Accepted,  ISSN  10837159

     View Summary

    Background: Proton pump inhibitors (PPIs) reduce the bioavailability of several anticancer drugs. The impact of PPIs co-administered with cyclin-dependent kinase 4 and 6 inhibitors is controversial. We aimed to clarify whether the concomitant use of PPIs impacts palbociclib and abemaciclib effectiveness in breast cancer treatment.
    Patients and Methods: This multicenter, retrospective, observational study, conducted across four medical institutions in Japan, consecutively included patients with endocrine-resistant metastatic breast cancer, receiving palbociclib or abemaciclib between December 2017 and August 2022. Propensity score-matched analyses were performed. Treatment efficacy and safety with and without PPIs were compared. Progression-free survival and overall survival were estimated using the Kaplan–Meier method and compared using a log-rank test. A Cox proportional hazards model was used to estimate the hazard ratio.
    Results: The study included 240 patients. After 1:1 matching, 112 patients were treated with and without PPIs. The median progression-free survival periods were 1.2 years in the PPI group and 1.3 years in the non-PPI group (hazard ratio, 1.19; 95% confidence interval [CI], 0.70–2.02). The median overall survival period was 3.6 years in the PPI group, whereas it was not reached in the non-PPI group (hazard ratio, 1.23; 95% CI, 0.61–2.47). Consistent results were obtained for subgroups receiving palbociclib (n = 177) and abemaciclib (n = 63) without propensity score matching. Moreover, adverse event incidence and severity were similar in both groups.
    Conclusion: The effectiveness of cyclin-dependent kinase 4/6 inhibitors is unlikely to be affected by concomitant PPI use. Future prospective pharmacokinetic studies are warranted.

  • Using an online journal club to improve Asian speakers’ comfort in using English to discuss and understand research papers written in English

    Tsuchiya M, Saeteaw M, Subongkot S, Tharnpanich T, Konmun J, Nasu I, Shimanuki Y, Tsuchitani T, Ezura M, Hashiguchi K, Bryan JC, Kawazoe H*

    Journal of Oncology Pharmacy Practice (SAGE PUBLICATIONS LTD)  in press. 2024.03

    Research paper (scientific journal), Joint Work, Last author, Corresponding author, Accepted

     View Summary

    Introduction: This study aimed to evaluate the participants’ comfort in understanding research papers written in English and discussing such research in English via an Asian online journal club.
    Methods: A self-administered online survey was delivered to seven journal club meeting attendees from July 2020 to July 2021. A customer satisfaction analysis was performed to assess the association between the participants’ perspectives on program logistics and satisfaction.
    Results: The recovery rate was 37.0% (44/119). After participating in the journal club, the median scores of critical appraisal skills, knowledge and/or pharmaceutical care skills in clinical practice, and discussion skills in English (assessed using a seven-point Likert scale) improved significantly (compared to pre-participation median scores) from 4 (interquartile range [IQR]: 3–5) to 5 (IQR: 4–6), 5 (IQR: 4–5) to 5 (IQR: 5–6), and 4 (IQR: 2–5) to 5 (IQR: 3–5), respectively (P < 0.0001). The respondents also expressed great appreciation for the benefits and overall qualities of the journal club. Additionally, regarding patient care behavior after participation in the journal club, 34 (77.3%), 17 (38.6%), 16 (36.4%), and 14 (31.8%) respondents reported improvement in “drug information services,” “patient assessments,” “patient counseling,” and “multidisciplinary rounds,” respectively. Customer satisfaction analysis revealed that sharing information, mutual discussion, a shift system of presenters and co-chairs, and session duration should be improved as a matter of highest priority.
    Conclusion: The findings suggest that our program could be helpful for Asian pharmacists, pharmacy students, and faculty members of the department of pharmacy.

  • Pharmacokinetics/pharmacodynamics analysis and establishment of optimal dosing regimens using unbound cefmetazole concentration for patients infected with Extended-Spectrum β-lactamase producing Enterobacterales (ESBL-E)

    Namiki T, Yokoyama Y, Hashi H, Oda R, Jibiki A, Kawazoe H, Matsumoto K, Suzuki S, Nakamura T

    Pharmacotherapy (WILEY)  44 ( 2 ) 149 - 162 2024.02

    Research paper (scientific journal), Joint Work, Accepted

  • Drug Repositioning Study on the Antiemetic Efficacy of Anamorelin for Cisplatin-Induced Nausea and Vomiting in Rats

    Nishino H†, Kawazoe H†*, Sekiguchi M, Jibiki A, Yokoyama Y, Suzuki S, Nakamura T

    BPB Reports (The Pharmaceutical Society of Japan)  7 ( 1 ) 1 - 6 2024.01

    Research paper (scientific journal), Joint Work, Corresponding author, Accepted

     View Summary

    Objective: Platinum- and anthracycline-based chemotherapy regimens cause nausea and vomiting in clinical practice, resulting in the deterioration of patients’ QoL, discontinuation of chemotherapy, and reduced therapeutic outcomes. Using pica behavior as an indicator, we aimed to clarify whether anamorelin, an orally active ghrelin receptor agonist, exerts antiemetic effects against cisplatin-induced nausea and vomiting in rats.
    Materials and methods: Sprague–Dawley rats were treated with cisplatin (5 mg/kg, i.p.), three-drug or four-drug antiemetics (granisetron [0.3 mg/kg, p.o.], dexamethasone [1.5 mg/kg, p.o.], fosaprepitant [12.5 mg/kg, i.p.], with or without anamorelin [30 mg/kg, p.o.]). Data on kaolin intake, normal food intake, and spontaneous motor activity (SMA) were recorded 1 d before and 5 d after cisplatin administration. Body weight (BW) was measured daily, and the percentage change in BW from baseline was calculated.
    Results: At the primary endpoint, kaolin intake was significantly higher in the cisplatin-only group than in the pretreatment and vehicle groups (p < 0.05). Additionally, kaolin food intake was not significantly low in cisplatin-treated mice treated with three-drug antiemetics with or without anamorelin. At the secondary endpoints, normal food intake, SMA, and percentage change in BW were significantly lower in the cisplatin-only group than in the vehicle group.
    Conclusion: Our findings suggest that the prophylactic administration of standard three-drug antiemetics, besides anamorelin, may not improve cisplatin-induced nausea and vomiting. Further studies using methods suitable for evaluating anamorelin levels are required.

  • Influence of menopause on chemotherapy‐induced nausea and vomiting in highly emetogenic chemotherapy for breast cancer: A retrospective observational study

    Yokokawa T, Suzuki K, Tsuji D, Hosonaga M, Kobayashi K, Kawakami K, Kawazoe H, Nakamura T, Suzuki W, Sugisaki T, Aoyama T, Hashimoto K, Hatori M, Tomomatsu T, Inoue A, Azuma K, Asano M, Takano T, Ohno S, Yamaguchi M

    Cancer Medicine (WILEY)  12 ( 18 ) 18745 - 18754 2023.10

    Research paper (scientific journal), Joint Work, Accepted,  ISSN  2045-7634

     View Summary

    Background: Female sex and younger age are reported risk factors for chemotherapy-induced nausea and vomiting (CINV) in highly emetogenic chemotherapy, but the underlying mechanism has not been elucidated. The purpose of this study was to clarify the impact of menopause on CINV.
    Methods: This retrospective observational study analyzed data from consecutive patients who received their first cycle of perioperative anthracycline-based chemotherapy for breast cancer between January 2018 and June 2020. The endpoints were association between CINV (vomiting, ≥Grade 2 nausea, complete response [CR] failure) and menopause as well as the association between CINV and follicle-stimulating hormone [FSH]/estradiol [E2].
    Results: Data for 639 patients were analyzed. Among these patients, 109 (17.1%) received olanzapine (four antiemetic combinations) and 530 (82.9%) did not (three antiemetic combinations). Premenopausal state (amenorrhea lasting ≥12 months) was significantly associated with ≥Grade 2 nausea and CR failure in univariate analysis but not in multivariate analysis. The premenopausal FSH/E2 group (defined by serum levels; FSH <40 mIU/mL and E2 ≥20 pg/mL) had a significantly higher rate of ≥Grade 2 nausea than the postmenopausal FSH/E2 group (FSH ≥40 mIU/mL and E2 <20 pg/mL) (48.8% vs. 18.8%, p = 0.023).
    Conclusions: Our results suggest that changes in FSH and E2 due to menopause may affect the severity of nausea and that FSH and E2 (especially FSH) levels might be useful indicators for CINV risk assessment.

display all >>

Papers, etc., Registered in KOARA 【 Display / hide

Reviews, Commentaries, etc. 【 Display / hide

  • 臨床的課題解決を目指した研究を行う次世代リーダーの養成~持続可能な研究活動を行うため~

    河添 仁

    薬学教育 ((一社)日本薬学教育学会)  7   1 - 3 2023.12

    Article, review, commentary, editorial, etc. (scientific journal), Single Work, Lead author, Last author, Corresponding author,  ISSN  2432-4124

  • 免疫チェックポイント阻害薬の有効性に影響を及ぼす併用薬と腸内細菌叢の臨床及び基礎研究

    河添 仁

    薬学研究の進歩 (公益財団法人薬学研究奨励財団)  39   71 - 75 2023.04

    Article, review, commentary, editorial, etc. (scientific journal), Single Work, Lead author, Last author, Corresponding author,  ISSN  0914-4544

  • 2022年度海外研修等参加報告書 MASCC/ISOO2022@virtualに参加して

    河添 仁

    医療薬学 ((一社)日本医療薬学会)  49 ( 2 ) 75 - 76 2023.02

    Article, review, commentary, editorial, etc. (scientific journal), Single Work, Lead author, Last author, Corresponding author,  ISSN  1346-342X

  • カペシタビンと胃酸分泌抑制薬の薬物間相互作用の解明に向けた多施設共同臨床研究及び基礎研究

    河添 仁, 北爪賀子, 魚住龍史, 吉澤朝枝, 飯原大稔, 藤井宏典, 高橋正也, 新井隆広, 村地 康, 佐藤由美子, 三上貴弘, 橋口宏司, 山崎朋子, 高橋克之, 藤田行代志, 細川祐岐, 諸角一成, 土屋雅美, 横山 敦, 橋本浩伸, 山口正和, 古川哲也, 関口真由, 平井光成, 秋山雅博, 金 倫基, 中村智徳

    医療の広場 (公益財団法人政策医療振興財団)  62 ( 10 ) 11 - 14 2022.10

    Article, review, commentary, editorial, etc. (scientific journal), Joint Work, Lead author, Last author, Corresponding author

  • がん化学療法に伴う有害反応の回避あるいは軽減を目的とした臨床薬学的研究の取り組みと臨床アウトカム

    河添 仁, 中村智徳

    医療薬学 ((一社)日本医療薬学会)  46 ( 9 ) 467 - 480 2020.09

    Article, review, commentary, editorial, etc. (scientific journal), Joint Work,  ISSN  1346-342X

     View Summary

    一般的に,悪性腫瘍に対するがん化学療法のリスクとベネフィットのバランスが重要になる.薬剤師は支持療法やがん化学療法の適正使用を通じて,がん化学療法に伴う有害反応を回避あるいは軽減させることで,ベネフィットを高めることが可能である.その結果,患者の生活の質を維持するだけでなく,がん化学療法の中止や減量を防ぐことに繋がる.薬剤師はがん化学療法に伴う有害反応の回避あるいは軽減を目的とした臨床薬学的研究を行うことが可能である.薬剤師は実臨床で感じた「臨床的疑問」を「研究的疑問」に変換して課題解決を行うことができる.本稿では,がん化学療法誘発性悪心・嘔吐(CINV)と血管痛を取り上げる.近年,制吐療法は著しい発展を遂げ,CINV 予防に関するたくさんのエビデンスが得られ,制吐薬の適正使用に関する国内外の複数のガイドラインが整備されている.しかし一方で,がん化学療法に伴う血管痛は患者の治療継続に直接的な影響を及ぼさないため,臨床家や研究者が見落とすことが多い.その結果,制吐薬,抗生物質及び顆粒球コロニー形成刺激因子製剤などの支持療法がない血管痛対策はエビデンスが乏しい.このような対照的な研究背景から,本稿では薬剤師がCINV とゲムシタビン誘発性血管痛の現状課題から遭遇する「臨床的疑問」を述べる.また,それらの「臨床的疑問」を「研究的疑問」に変換して薬剤師が研究に着手した臨床薬学的研究から得られる成果について述べる.

display all >>

Presentations 【 Display / hide

  • Use of proton pump inhibitors and cyclin-dependent kinase 4/6 inhibitors in patients with endocrine-resistant metastatic breast cancer

    Kawazoe H, Takahashi K, Uozumi R, Mukohara T, Hayashida T, Iwabe M, Iihara H, Kusuhara-Mamishin K, Kitagawa Y, Tsuchiya M, Kitahora M, Nagayama A, Kosaka S, Asano-Niwa Y, Seki T, Ohnuki K, Suzuki A, Ono F, Futamura M, Nakamura T

    MASCC/AFSOS/ISOO 2024 Annual Meeting, Lille, 

    2024.06

    Poster presentation

  • MIRTAZAPINE COMBINED WITH DOUBLET THERAPY FOR THE PREVENTION OF CARBOPLATIN-INDUCED NAUSEA AND VOMITING IN PATIENTS WITH THORACIC MALIGNANCIES

    Kitamura Y, Iihara H, Iwai M, Morita R, Fujita Y, Ohgino K, Ishihara T, Hirose C, Suzuki Y Masubuchi K, Kawazoe H, Kawae D, Aihara K, Endo S, Fukunaga K, Yamazaki M, Tamura T, Fukui S, Endo J, Suzuki A

    MASCC/AFSOS/ISOO 2024 Annual Meeting, Lille, 

    2024.06

    Poster presentation

  • CDK4/6阻害薬の有効性に対するプロトンポンプ阻害薬併用の影響:多機関共同後方視的観察研究

    北洞美佳, 魚住龍史, 髙橋佳織, 向原 徹, 林田 哲, 岩部 翠 , 飯原大稔, 河添 仁, 楠原佳那子, 永山愛子, 土屋雅美, 丹羽好美, 中村智徳, 小坂真吉, 二村 学, 関 朋子, 大貫幸二, 鈴木昭夫

    日本臨床腫瘍薬学会学術大会2024, 

    2024.03

    Oral presentation (general)

  • 基質特異性拡張型β-ラクタマーゼ産生腸内細菌目細菌感染患者に対する遊離形セフメタゾール濃度を用いたPPK/PD解析と最適投与法の構築

    並木孝哉, 横山雄太, 枦 秀樹, 織田錬太郎, 地引 綾, 河添 仁, 松元一明, 鈴木小夜, 中村智徳

    第44回日本臨床薬理学会学術総会, 

    2023.12

    Oral presentation (general)

  • 病院薬剤師のキャリアビジョンに対する意識調査

    河添 仁, 土屋雅美, 藤堂真紀, 原 梓, 大西友美子, 堀 里子

    第33回日本医療薬学会年会, 

    2023.11

    Poster presentation

display all >>

Research Projects of Competitive Funds, etc. 【 Display / hide

  • CDK4/6阻害薬と胃酸分泌抑制薬の薬物相互作用の解明に向けた臨床・基礎融合研究

    2023.06
    -
    2024.03

    公益財団法人政策医療振興財団, (公財)政策医療振興財団研究助成, Research grant, Principal investigator

  • パルボシクリブと胃酸分泌抑制薬の薬物相互作用の臨床・基礎融合研究

    2023.04
    -
    2024.03

    慶應義塾, 福澤基金研究補助, Research grant, Principal investigator

  • バンコマイシンのAUC指標TDMの臨床実装とその評価

    2022.12
    -
    2023.11

    公益財団法人ファイザーヘルスリサーチ振興財団, 第31回(2022年度)ヘルスリサーチ研究助成 国内共同研究(年齢制限なし), Research grant, Principal investigator

  • 腸内細菌叢と腫瘍免疫応答の関連性及びそのメカニズム解明

    2022.11
    -
    2023.12

    日本イーライリリー株式会社, 2022年度研究助成(従来型), Research grant, Principal investigator

  • Influence of gut microbiota on the effectiveness of immune checkpoint inhibitors and elucidation of the mechanism

    2022.04
    -
    2025.03

    文部科学省・日本学術振興会, 文部科学省科学研究費(基盤研究C), Research grant, Principal investigator

display all >>

Awards 【 Display / hide

  • 日本臨床腫瘍薬学会学術大会2024優秀演題賞

    北洞美佳, 魚住龍史, 髙橋佳織, 向原 徹, 林田 哲, 岩部 翠 , 飯原大稔, 河添 仁, 楠原佳那子, 永山愛子, 土屋雅美, 丹羽好美, 中村智徳, 小坂真吉, 二村 学, 関 朋子, 大貫幸二, 鈴木昭夫, 2024.03, 日本臨床腫瘍薬学会学術大会2024, CDK4/6阻害薬の有効性に対するプロトンポンプ阻害薬併用の影響:多機関共同後方視的観察研究

    Type of Award: Award from Japanese society, conference, symposium, etc.

  • 第44回日本臨床薬理学会学術総会優秀発表賞

    並木孝哉, 横山雄太, 枦 秀樹, 織田錬太郎, 地引 綾, 河添 仁, 松元一明, 鈴木小夜, 中村智徳, 2023.12, 第44回日本臨床薬理学会学術総会, 基質特異性拡張型β-ラクタマーゼ産生腸内細菌目細菌感染患者に対する遊離形セフメタゾール濃度を用いたPPK/PD解析と最適投与法の構築

    Type of Award: Award from Japanese society, conference, symposium, etc.

  • 第8回日本薬学教育学会大会優秀発表賞

    牧山大輝, 松野昂樹, 小林聡太, 野々宮菜彌, 地引 綾, 横山雄太, 河添 仁, 津田壮一郎, 大谷壽一, 中村智徳, 鈴木小夜, 2023.08, 第8回日本薬学教育学会大会, フィードバックと省察ワークシートによる介入が病院実務実習生のプロフェッショナリズム評価と省察能力に与えた影響

    Type of Award: Award from Japanese society, conference, symposium, etc.

  • 第16回日本性差医学・医療学会学術集会優秀演題賞

    地引 綾, 村上紗恵子, 吉野鉄大, 堀場裕子, 横山雄太, 河添 仁, 鈴木小夜, 渡辺賢治, 中村智徳, 2023.02, 第16回日本性差医学・医療学会学術集会, 更年期症状に対する漢方治療不応例の分析

    Type of Award: Award from Japanese society, conference, symposium, etc.

  • 第32回日本医療薬学会年会 YIA(Young Investigator's Award)(社会人部門)

    並木孝哉, 横山雄太, 枦 秀樹, 地引 綾, 河添 仁, 松元一明, 鈴木小夜, 中村智徳, 2022.09, 第32回日本医療薬学会年会, ESBL産生腸内細菌科細菌に対する血液透析患者の遊離形CMZ濃度を用いたPK/PDに基づく最適投与法の評価

    Type of Award: Award from Japanese society, conference, symposium, etc.

display all >>

 

Courses Taught 【 Display / hide

  • STUDY OF MAJOR FIELD: (PHARMACEUTICAL CARE SCIENCES)

    2024

  • SEMINAR: (PHARMACEUTICAL CARE SCIENCES)

    2024

  • RESEARCH FOR BACHELOR'S THESIS 1

    2024

  • PRIOR LEARNING FOR CLINICAL PRACTICE 3

    2024

  • PRE-CLINICAL TRAINING FOR HOSPITAL & COMMUNITY PHARMACY

    2024

display all >>

Courses Previously Taught 【 Display / hide

  • 卒業研究B

    Keio University

    2018.04
    -
    2019.03

  • 卒業研究A

    Keio University

    2018.04
    -
    2019.03

  • 薬局実務実習

    Keio University

    2018.04
    -
    2019.03

  • 病院実務実習

    Keio University

    2018.04
    -
    2019.03

  • 実務実習の前に(6)

    Keio University

    2018.04
    -
    2019.03

display all >>

 

Social Activities 【 Display / hide

  • 日本医療薬学会 2024年度医療薬学学術第3小委員会「生成系AIの薬剤師業務への応用に関する実態、課題やニーズの調査」研究班

    2024.04
    -
    2026.03
  • 日本病院薬剤師会 令和5年度学術第6小委員会「病院薬剤師の働き方・キャリア支援」研究班

    2023.07
    -
    2025.06
  • 日本がん薬剤学会 研究推進委員会

    2022.06
    -
    Present
  • 日本臨床腫瘍薬学会 実地研修委員会

    2022.04
    -
    Present
  • 日本臨床腫瘍薬学会 理事

    2022.03
    -
    2024.03

display all >>

Memberships in Academic Societies 【 Display / hide

  • Multinational Association of Supportive Care in Cancer (MASCC), 

    2024.04
    -
    Present
  • 日本がん薬剤学会, 

    2022.04
    -
    Present
  • 日本薬学会, 

    2019.08
    -
    Present
  • 日本MBTI協会, 

    2018.12
    -
    Present
  • 東京都病院薬剤師会, 

    2018.04
    -
    Present

display all >>